Novel pharmaceutical compositions and methods for treating insomnia

Using anti-inflammatory and sleep-promoting effects of existing insomnia treatments through azelastine and melatonin compositions, it addresses the side effects of existing insomnia treatments, providing a new treatment for a wide range of patient populations, significantly reducing insomnia Symptoms and reduce side effects.

CN119012916APending Publication Date: 2024-11-22LA PHARMATECH INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202280094860.9
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2022-02-16
Publication Date
2024-11-22

AI Technical Summary

Technical Problem

Existing insomnia treatment drugs have side effects such as tolerability, dependence, memory impairment, depression, headache, dizziness, and lethargy, and are not applicable to patients with other medical or mental conditions, and there is a lack of new treatments for significant side effects.

Method used

Using a composition of azelastine and melatonin, azelastine has anti-inflammatory effects as an antihistamine, and melatonin has sleep-promoting activity, and is used in combination to treat insomnia by inhibiting inflammatory mediators and stabilizing mast cells. .

Benefits of technology

The composition significantly reduces symptoms of insomnia such as difficulty falling asleep, night wakeup and daytime fatigue, and has shown fewer side effects in clinical trials and is suitable for a wider range of insomnia patients, including other medical or mental conditions. patient.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

A pharmaceutical composition comprising azelastine or a pharmaceutically acceptable salt of azelastine and a melatonin is disclosed. Also disclosed are methods of using the pharmaceutical compositions to treat patients suffering from insomnia.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS

[0002] This application is a continuation-in-part of U.S. patent application No. 16 / 884,459 filed on May 27, 2020 (which is a continuation-in-part of U.S. patent application No. 16 / 382,885 filed on April 12, 2019), the disclosure of which is incorporated herein by reference in its entirety. Technical Field

[0003] The present invention relates to the field of practical medicine, namely, to the use of a pharmaceutical composition for treating, preventing and / or alleviating the clinical manifestations of insomnia or its symptoms. Background Art

[0004] Insomnia is often diagnosed by polysomnographic evidence of sleep disturbances such as long sleep latency, frequent nighttime awakenings, or long-term wakefulness or even frequent short awakenings during sleep. Various population-based studies show that about 30%-40% of the various adult samples obtained from different countries reported one or more symptoms of insomnia: difficulty falling asleep, difficulty maintaining sleep, waking up too early, and in some cases, non-restorative sleep or poor sleep quality. Particularly, insomnia has a very negative impact on the vulnerable patient population including active military personnel and veterans, patients suffering from mental illness and medical illness simultaneously, those in life transitions such as menopause, and the elderly. Due to the chronicity of insomnia, insomnia is related to the incidence of high mental complications such as the substantial damage of individual quality of life. Insomnia even causes greater health risks due to the increased daytime accident rate.

[0005] Treatments for insomnia include benzodiazepine receptor agonists, such as triazolam, estazolam, zolpidem, zaleplon, eszopiclone, etc.; melatonin agonists, such as ramelteon; tricyclic antidepressants, such as doxepin; orexin receptor antagonists, such as suovorexin. These drugs do carry the risk of tolerance, dependence, memory impairment, depression, headache, dizziness, drowsiness, etc.

[0006] Clinically, there is an urgent need for new treatments for insomnia that have significantly fewer side effects and can be made available to a wider range of patients experiencing insomnia who suffer from other medical or psychiatric conditions.

[0007] Inflammation can be defined as one of the immune responses used to protect an organism from damage. The immune system can be triggered by various factors such as pathogens, damage to cells and stress, which may induce acute or chronic inflammatory responses in organs including the brain, potentially leading to tissue damage or disease. Recent advances in neurobiological research provide more and more evidence that inflammatory pathways and neurodegenerative pathways play a relevant role in insomnia. Preclinical and clinical studies on insomnia have highlighted the increased production of inflammatory markers such as interleukin (IL)-1, IL-6, tumor necrosis factor (TNF)-α, and interferon (INF)-α and γ, and inflammatory signaling pathways including over-activation of nuclear factor kappa B (NF-κB). More recent studies have shown that blocking the biological effects of cytokines IL-1 and TNF leads to a reduction in the amount of physiological NREM sleep or NREM sleep rebound after sleep deprivation. On the other hand, increasing the availability of these cytokines promotes the amount and intensity of NREM sleep and suppresses the amount of REM sleep. These findings confirm that both cytokines IL-1 and TNF are substances involved in the homeostatic regulation of sleep. Other cytokines, including IFN, IL-2, IL-4, IL-6, IL-10, IL-13, IL-15, and IL-18, also appear to have some sleep-regulating properties. The anti-inflammatory cytokines IL-4, IL-10, and IL-13 reportedly reduce the amount of NREM sleep in rabbits, whereas the pro-inflammatory cytokines IFN-γ, IL-2, IL-6, IL-15, and IL-18 have the effect of promoting NREM sleep in animal models.

[0008] Azelastine is pharmacologically classified as a second-generation antihistamine and is a relatively selective, non-sedating, H1 receptor competitive antagonist used to treat allergic rhinitis and asthma. However, more uniquely, in addition to its antihistamine activity, its inhibition of inflammatory mediators and stabilizing effects on mast cells make it one of the new generation of dual-acting anti-inflammatory drugs. Its ability to alter several other inflammatory mediators such as IL-1, IL-6, TNF-α and INF-α and reduce overactivation of the NF-κB inflammatory signaling pathway may contribute to its mechanism of action for the potential treatment of insomnia. In vitro and in vivo studies and clinical trials support the dual effects of direct inhibition and stabilization of inflammatory cells. In vitro data suggest that azelastine's inhibitory affinity for mast cell degranulation can also reduce the release of other inflammatory mediators including leukotrienes and interleukin-1β. Preclinical studies have shown that azelastine also directly antagonizes other inflammatory mediators such as tumor necrosis factor-α, leukotrienes, endothelin-1, and platelet-activating factor.

[0009] Melatonin is best known for its ability to regulate annual changes in metabolism and reproductive capacity in light-sensitive species, its ability to influence circadian processes that are ubiquitous in organisms and in cells, and its sleep-promoting activity. Each of these functions depends on circadian information provided by blood and cerebrospinal fluid melatonin rhythms derived from the pineal gland. Melatonin is also highly effective as an antioxidant at the mitochondrial level and is also an anti-inflammatory agent. Doses used for membrane receptor-mediated circadian regulation are generally lower than those used to defeat free radicals (an effect that is independent of membrane receptors). It is believed that high doses of melatonin are effective in alleviating the excessive production of inflammatory markers such as interleukin (IL) -1, IL-6, and tumor necrosis factor (TNF) -α.

[0010] Therefore, the unique combination of azelastine, an antihistamine with anti-inflammatory activity, and melatonin may potentially be effective in the treatment of insomnia, acting through multiple mechanisms of action. Summary of the invention

[0011] The present invention includes a pharmaceutical composition comprising two active pharmaceutical ingredients. The pharmaceutical composition comprises a first active ingredient which is azelastine or a pharmaceutically acceptable salt of azelastine and a second active ingredient which is melatonin.

[0012] In some embodiments of the present invention, the pharmaceutically acceptable salt of azelastine in the pharmaceutical composition is azelastine hydrochloride.

[0013] In some embodiments of the present invention, azelastine hydrochloride (and / or other salts of azelastine) is provided in an amount of about 2 mg to about 10 mg and melatonin is provided in an amount of about 2 mg to about 20 mg in the pharmaceutical composition.

[0014] The present invention also includes oral pharmaceutical dosage forms of the pharmaceutical composition, which are in the form of solid, liquid, gel or solution.

[0015] The invention also includes the use of the composition, for example by oral dosage, by administration to a patient suffering from insomnia.

[0016] In some embodiments of the present invention, an oral pharmaceutical dosage form of a pharmaceutical composition comprising azelastine hydrochloride (and / or other salts of azelastine) in an amount of about 2 mg to about 10 mg and melatonin in an amount of about 2 mg to about 20 mg is administered to a patient suffering from insomnia.

[0017] Embodiments include aspect 1, which is a pharmaceutical composition comprising: azelastine or a pharmaceutically acceptable salt of azelastine; melatonin; and one or more pharmaceutically acceptable excipients.

[0018] Aspect 2 is the pharmaceutical composition of aspect 1, wherein azelastine or a pharmaceutically acceptable salt of azelastine is present in the pharmaceutical composition in an amount ranging from about 1 mg to about 10 mg.

[0019] Aspect 3 is the pharmaceutical composition of aspect 1 or 2, wherein melatonin is present in the pharmaceutical composition in an amount ranging from about 2 mg to about 20 mg.

[0020] Aspect 4 is the pharmaceutical composition of any of aspects 1-3, wherein melatonin is present in the pharmaceutical composition in an amount ranging from about 2 mg to about 20 mg.

[0021] Aspect 5 is the pharmaceutical composition of any of Aspects 1-4, wherein: azelastine or a pharmaceutically acceptable salt of azelastine is present in the pharmaceutical composition in an amount ranging from about 1 mg to about 10 mg; and melatonin is present in the pharmaceutical composition in an amount ranging from about 5 mg to about 20 mg.

[0022] Aspect 6 is the pharmaceutical composition of any of Aspects 1-5, wherein the pharmaceutically acceptable salt of azelastine is azelastine hydrochloride.

[0023] Aspect 7 is the pharmaceutical composition of any of Aspects 1-6, wherein the pharmaceutically acceptable salt of azelastine is azelastine hydrochloride.

[0024] Aspect 8 is the pharmaceutical composition of any of Aspects 1-7, wherein the pharmaceutically acceptable salt of azelastine is azelastine hydrochloride, and azelastine hydrochloride is present in the pharmaceutical composition and is present in an amount of up to about 10 mg.

[0025] Aspect 9 is the pharmaceutical composition of any of aspects 1-8, wherein azelastine hydrochloride is present in an amount ranging from about 1 mg to about 10 mg.

[0026] Aspect 10 is the pharmaceutical composition of any of aspects 1-9, wherein the pharmaceutical composition is formulated as an oral pharmaceutical dosage form.

[0027] Aspect 11 is the pharmaceutical composition of any of aspects 1-10, wherein the oral dosage form is in solid form or liquid form.

[0028] Aspect 12 is a method comprising: administering a pharmaceutical composition to a patient suffering from insomnia or a symptom thereof; wherein the pharmaceutical composition comprises azelastine or a pharmaceutically acceptable salt of azelastine and melatonin.

[0029] Aspect 13 is the method of aspect 12, wherein the pharmaceutical composition is administered to the patient in oral solid or liquid form once or twice a day or once every 2 days, 3 days or 4 days.

[0030] Aspect 14 is the method of aspect 12 or 13, wherein azelastine or a pharmaceutically acceptable salt of azelastine is present in the pharmaceutical composition in an amount ranging from about 1 mg to about 10 mg.

[0031] Aspect 15 is the method of any of aspects 12-14, wherein melatonin is present in the pharmaceutical composition in an amount ranging from about 2 mg to about 20 mg.

[0032] Aspect 16 is the method of any of aspects 12-15, wherein melatonin is present in the pharmaceutical composition in an amount ranging from about 2 mg to about 20 mg.

[0033] Aspect 17 is the method of any of aspects 12-16, wherein azelastine or a pharmaceutically acceptable salt of azelastine is present in the pharmaceutical composition in an amount ranging from about 4 mg to about 10 mg.

[0034] Aspect 18 is the method of any of aspects 12-17, wherein azelastine or a pharmaceutically acceptable salt of azelastine and melatonin are present in the pharmaceutical composition in synergistically effective amounts.

[0035] Aspect 19 is the method of any of aspects 1-18, wherein the pharmaceutical composition is administered to the patient for a period of up to 8 weeks.

[0036] Aspect 20 is the method of any of aspects 1-19, wherein the pharmaceutical composition is administered to the patient for a period of at least 4 weeks.

[0037] Aspect 21 is the use of a pharmaceutical composition for the preparation of a medicament for treating a patient suffering from insomnia or one or more symptoms thereof, wherein the pharmaceutical composition comprises the composition of any of claims 1-11 and / or the use involves any of the methods or method steps of claims 12-20.

[0038] Aspect 22 is a pharmaceutical composition for use in treating insomnia or one or more symptoms thereof, wherein the medicament comprises the composition of any of claims 1-11 and / or the use involves any of the methods or method steps of claims 12-20. DETAILED DESCRIPTION

[0039] Through clinical practice, the inventors of the present invention have found that a pharmaceutical composition having an oral dosage form comprising active agents (a salt form of azelastine and melatonin) is suitable for treating patients suffering from insomnia and / or its symptoms such as difficulty falling asleep, waking up at night, waking up too early, daytime tiredness / sleepiness, etc.

[0040] The subject matter of this application is related to International Patent Application Nos. PCT / US19 / 27293, PCT / US19 / 29885, PCT / US19 / 33359, PCT / US20 / 34735, PCT / US20 / 39916, PCT / US20 / 59846, and PCT / US21 / 44654, each of which is hereby incorporated by reference in its entirety.

[0041] The detailed description provided below is intended as a description of this example and is not intended to represent the only form in which this example can be constructed or utilized. This description sets forth the functions of the example and the order of the steps of constructing and operating the example. However, the same or equivalent functions and order can be implemented by different examples.

[0042] definition

[0043] As used in this specification, the following words and phrases are generally intended to have the meanings set forth below, unless the context in which they are used indicates otherwise.

[0044] As used herein, the term "melatonin" refers to N-acetyl-5-methoxytryptamine.

[0045] As used herein, the term "azelastine" refers to azelastine free base or 4-(p-chlorobenzyl)-2-(hexahydro-1-methyl-1H-azepine -4-yl)-1-(2H)-phthalazino ne (4-(p-Chlorobenzyl)-2-(hexahydro-1-methyl-1H-azepin-4-yl)-1-(2H)-phthalazino ne). In certain embodiments, azelastine also includes any pharmaceutically acceptable salt, such as a hydrochloride or HCl salt. Preferably, in any embodiment of the present invention as described herein, azelastine is in the form of its hydrochloride salt, such as azelastine hydrochloride or azelastine HCl. More preferably, in any embodiment of the present invention as described herein, reference to the amount and dosage range of azelastine in a solid oral dosage form refers to the amount and dosage range of azelastine hydrochloride.

[0046] As used herein, "treating" or "treatment" means complete or incomplete cure, or it means at least a reduction and / or delay of the symptoms of the underlying disease or related condition, and / or a reduction, delay and / or elimination of one or more of the underlying cellular, physiological or biochemical causes or mechanisms of the symptoms. It should be understood that reduction or delay as used in this context means relative to the state of the untreated disease, including the molecular state of the untreated disease, not just the physiological state of the untreated disease.

[0047] The term "effective amount" refers to an amount sufficient to affect treatment when administered to a mammal in need of such treatment, as defined below. The therapeutically effective amount will vary depending on the patient being treated, the patient's weight and age, the severity of the disease condition, and the mode of administration, etc., which can be easily determined by one of ordinary skill in the art. The pharmaceutical composition can be administered orally in a single dose or multiple doses. It can be administered by any one or more of capsules, tablets, gels, sprays, drops, solutions, suspensions, or syrups, etc.

[0048] The term "about" used herein in the context of quantitative measurement means the specified amount ± 10%. For example, in the case of a ± 10% range, "about 2 mg" may mean 1.8-2.2 mg.

[0049] Pharmaceutical compositions can be formulated for pharmaceutical use using methods known in the art, for example, Ansel's Pharmaceutical Dosage Forms and Drug Delivery Systems, 10th Edition (Loyd Allen, 2013) and Handbook of Pharmaceutical Manufacturing Formulations (Volumes 1-6, Sarfaraz K. Niazi). Thus, the introduction of active compounds and controlled or sustained release matrices can be implemented.

[0050] Fluid or solid unit dosage forms can be easily prepared for oral administration, for example, with any one or more of conventional ingredients such as dicalcium phosphate, magnesium aluminum silicate, magnesium stearate, calcium sulfate, starch, talcum, lactose, gum arabic, methylcellulose and functionally similar materials as pharmaceutical excipients or carriers. Sustained release formulations can be optionally used. In older or incoherent subjects, even preferred sustained release formulations. Capsules can be prepared by mixing pharmaceutical compositions with inert pharmaceutical diluents and filling the mixture into hard gelatin capsules with appropriate size. If soft capsules are desired, the slurry of pharmaceutical compositions and acceptable vegetable oils, light petroleum or other inert oils can be encapsulated in gelatin capsules.

[0051] Suspension, syrup and elixir can be used for oral administration or fluid unit dosage form. Fluid preparations comprising oil can be used for oil-soluble forms. Vegetable oils such as corn oil, peanut oil or flower oil (flower oil) for example produce acceptable fluid preparations together with flavoring, sweetener and any preservative. Surfactant can be added to the water to form a syrup for fluid unit dosage. Water-alcohol (hydro-alcoholic) pharmaceutical preparations with acceptable sweeteners such as sugar, saccharin or other non-nutritional sweeteners and / or biological sweeteners and / or flavorings (for example in the form of elixir) can be used.

[0052] The solid oral dosage form of the present disclosure refers to the form of tablets, caplets, bilayer tablets, film-coated tablets, pills or capsules. The tablets according to the present disclosure can be prepared by any mixing and tableting techniques known to the pharmaceutical preparation industry. In some examples, the dosage form is manufactured by directly compressing the separately prepared sustained-release part and the immediate-release part by means of a punch and a die mounted to a rotary tablet press, ejecting or compression molding, or granulating after compression.

[0053] The pharmaceutical composition provided according to the present disclosure can generally be orally administered. Therefore, the present disclosure provides a pharmaceutical composition comprising a solid dispersion, the solid dispersion comprising azelastine and melatonin as described herein and one or more pharmaceutically acceptable excipients or carriers, the pharmaceutically acceptable excipients or carriers include but are not limited to inert solid diluents and fillers, diluents including sterile aqueous solutions and various organic solvents, penetration enhancers, solubilizers, disintegrants, lubricants, adhesives, glidants, adjuvants, and combinations thereof. Such compositions are prepared in a manner known in the pharmaceutical field (see, for example, Ansel's Pharmaceutical Dosage Forms and Drug Delivery Systems, 10th edition (Loyd Allen, 2013) and Handbook of Pharmaceutical Manufacturing Formulations (Volumes 1-6, Sarfaraz K. Niazi)).

[0054] The pharmaceutical composition may further comprise pharmaceutical excipients such as diluents, adhesives, fillers, glidants, disintegrants, lubricants, solubilizers and combinations thereof. Examples of some suitable excipients are described herein. When the pharmaceutical composition is formulated as tablets, the tablets may be uncoated or may be coated by the known techniques including microencapsulation to delay disintegration and absorption in the gastrointestinal tract and thus provide a longer sustained effect. For example, time-delay materials such as glyceryl monostearate or glyceryl distearate may be used alone or together with wax. In embodiments, the pharmaceutical composition is formulated as tablets, caplets, pills or capsules for gastrointestinal absorption, for example, formulated to delay disintegration until the pharmaceutical composition is in the gastrointestinal tract of the patient. In embodiments, coating is used to achieve delayed disintegration.

[0055] In an embodiment, the pharmaceutical composition may comprise synergistically effective amounts of azelastine and melatonin, such as a) about 1 mg to 10 mg azelastine HCl (or other salts of azelastine) and b) about 2 mg to 20 mg melatonin, or a) about 2 mg to 6 mg azelastine HCl (or other salts of azelastine) and b) about 4 mg to 10 mg melatonin, or a) about 2 mg to 4 mg azelastine HCl (or other salts of azelastine) and b) about 4 mg to 6 mg melatonin, or any amount of azelastine or melatonin within these ranges. In an embodiment, melatonin is present in a pharmaceutical composition in a synergistically effective amount relative to the amount of azelastine or a pharmaceutically acceptable salt of azelastine, and may include a pharmaceutical composition comprising a) about up to and including any of 1 mg, 2 mg, 3 mg, 4 mg, 5 mg, 6 mg, 7 mg 8 mg, 9 mg, or 10 mg of azelastine, such as azelastine HCl, or any amount within any of these ranges, and b) about up to and including any of 1 mg, 2 mg, 3 mg, 4 mg, 5 mg, 6 mg, 7 mg, 8 mg, 9 mg, 10 mg, 11 mg, 12 mg, 13 mg, 14 mg, 15 mg, 16 mg, 17 mg, 18 mg, 19 mg, or 20 mg of melatonin or any amount within any of these ranges. For example, a composition comprising synergistically effective amounts of melatonin and azelastine may comprise a) about 4 mg of azelastine HCl and b) about 6 mg of melatonin. In addition, for example, the composition of the present invention may include azelastine or a pharmaceutically acceptable salt of azelastine in an amount ranging from about 2 mg to about 10 mg and a synergistically effective amount of melatonin in an amount ranging from about 2 mg to about 20 mg. In embodiments, the synergistically effective amount may be such that the amount of azelastine HCl (or other salts of azelastine) present in the composition may be equal to, greater than, or less than the amount of melatonin present in the composition. In embodiments, the synergistically effective amount is such that azelastine is present in the pharmaceutical composition in an amount of at least 1 mg and melatonin is present in an amount of at least 0.1 mg. In embodiments, a synergistically effective amount may be such that the amount of azelastine HCl (and / or other salts of azelastine) present in the composition may be the same as, or 2 times, or 3 times, or 4 times, 5 times, 6 times, 7 times, 8 times, 9 times, 10 times, 15 times, 20 times, 25 times, 30 times, 35 times, 10 times, 15 times, or 50 times the amount of melatonin present in the composition, or vice versa. Any one or more compositions of the present invention may be used with any one or more methods of the present invention disclosed herein or other methods using the compositions.

[0056] It will be understood that the amount of the pharmaceutical composition comprising azelastine HCl and melatonin actually administered will generally be determined by a physician according to the relevant circumstances, including the condition to be treated, the route of administration chosen, the actual compounds administered and their relative activities, the age, weight and response of the individual patient, and the severity of the patient's symptoms, etc.

[0057] Pharmaceutical compositions, pharmaceutical dosage forms, and tablets as described herein comprising azelastine, e.g., azelastine HCl, and melatonin are administered to patients suffering from insomnia once a day, twice a day, up to four times a day, every other day, once a week, twice a week, three times a week, four times a week, or five times a week, or a combination thereof, e.g., orally.

[0058] In an embodiment, a pharmaceutical composition having a therapeutically effective daily dose of azelastine (eg, azelastine HCl) in the range of about 1 mg to about 10 mg and melatonin in an amount in the range of about 2 mg to about 10 mg is administered to a patient.

[0059] In embodiments, pharmaceutical dosage forms and tablets comprising a pharmaceutical composition of azelastine, e.g., azelastine HCl and melatonin as described herein are effective in reversing, alleviating, relieving and / or treating insomnia within about 1-8 weeks, e.g., within 1 week, 2 weeks, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 7 weeks, or 8 weeks, or any range therebetween.

[0060] The following examples are illustrative and should not be construed as limiting the scope of the claimed subject matter.

[0061] Example 1

[0062] A 61-year-old female patient has suffered from chronic insomnia for more than 18 months, with symptoms including difficulty falling asleep and waking up 2 to 3 times during sleep. She tried taking OTC antihistamine sleeping pills for 3 days, then taking melatonin (10 mg every day) for 3 days, and they were ineffective in the treatment of her insomnia. She used the antidepressant trazodone and then treated with doxepin, but her insomnia still persisted. After providing her with eszopiclone, her insomnia was eliminated after preliminary treatment, but she could not tolerate the side effect of headache caused by eszopiclone, and after she stopped taking eszopiclone, her insomnia recurred. Then, a combination of azelastine (4 mg every day) and melatonin (6 mg every day) of a synergistic effective amount was provided to her. Using this treatment, the combination of azelastine and melatonin has a synergistic effect, and her insomnia disappears after the 3rd day of treatment, while melatonin alone is ineffective for her insomnia. The treatment regimen lasted 8 weeks, and she experienced no side effects other than a mild metallic taste, and her insomnia did not recur.

[0063] Example 2

[0064] A 52-year-old female patient has been suffering from chronic insomnia for more than 6 months. She has difficulty falling asleep and sleeps less than 4 hours per night. She tried to take melatonin (10 mg per day) as a preliminary treatment but was unsuccessful. She was prescribed eszopiclone and her sleep time increased to about 6 hours, but she experienced dizziness and nausea during the day after 2 weeks of treatment and she had to stop taking eszopiclone. Then, after not taking eszopiclone for a week, she began to experience insomnia again. A combination of azelastine (4 mg) and melatonin (6 mg) in a synergistically effective amount was provided to her every day. Using this treatment, the combination of azelastine and melatonin has a synergistic effect, and she can sleep 6-7 hours a day, while melatonin alone is unsuccessful. In the case of only experiencing bitter mouth, the patient is very satisfied with the treatment.

[0065] Example 3

[0066] A 47-year-old male patient has suffered from chronic insomnia for more than 4 months. He has difficulty falling asleep and sleeps 5 to 6 hours every night, which causes daytime sleepiness and very often prevents him from carrying out his regular work tasks. In the course of 3 months, in order to treat his insomnia, he took diazepam for 7 days, then took zolpidem for 7 days, and then took eszopiclone for 2 weeks, but he could not tolerate these treatments due to the side effects of drowsiness, dizziness and headache, because these side effects prevented him from carrying out his regular work tasks like his insomnia. A combination of azelastine (6 mg every day) and melatonin (6 mg every day) was provided to him. After 3 days of treatment, he could sleep 6-7 hours a day and did not experience drowsiness, dizziness or headache during the day. He was treated for 6 weeks without complaints of intolerable side effects.

[0067] References

[0068] A. Menendez Pelaez, and RJ Reiter, "Distribution of melatonin inmammalian tissues: The relative importance of nuclear versus cytosolic localization". J. Pineal Res. 1993, 15: 59-69.

[0069] F.Auld,F.,E.Le Maschauer,et al.,“Evidence for the efficacy ofmelatonin in the treatment of primary adult sleep disorders”.SleepMed.Rev.2017,34:10-22.

[0070] R.Hardeland,“Neurobiology,pathophysiology,and treatment of melatonindeficiency and dysfunction”.The Scientific World Journal 2012,Article ID640389.

[0071] D.Acuna-Castroviejo,G.Escames,et al.“Melatonin role in themitochondrial function”.Frontiers in Bioscience.2007 12:947-963.

[0072] C.D.Acuna,L.C.Lopez,et al,“Melatonin-mitochondria interplay inhealthand disease”.Current Topics in Med.Chem.2011,11:221-240.

[0073] R.J.Reiter,D.X.Tan,and A.Galano,“Melatonin:Exceeding expectations”.Physiology 2014,29:325-333.

[0074] G.Patki and Y.S.Lau,“Melatonin protects against neurobehavioralandmitochondrial deficits in a chronic mouse model of Parkinson’s disease”.Pharmacol.Biochem.Behav.2011,99:704-711.

[0075] R.J.Reiter,J.C.Mayo,et al.,“Melatonin as an antioxidant:Underpromisesbut over delivers”.J.Pineal Res.2016,61:253-278.

[0076] Wei-jie Lv,C.Liu et al,“Melatonin Alleviates NeuroinflammationandMetabolic Disorder in DSS-Induced Depression Rats”.Oxidative MedicineandCellular Longevity 2020,Article ID 1241894.

[0077] Mónica de la Bravo,L.D.Serpero,et al,“Inflammatory proteinsinpatients with obstructive sleep apnea with and without daytime sleepiness”.Sleep Breath,2007 Sep;11(3):177-85.

[0078] R.Nadeem,J.Molnar,et al.,Serum inflammatory markers inobstructivesleep apnea:a meta-analysis,Journal of Clinic Sleep Med(2013)Oct15;9(10):1003-12.

[0079] J.Gaines,A.N.Vgontzas,et al,“Inflammation mediates theassociationbetween visceral adiposity and obstructive sleep apnea inadolescents”Am J.Physiol.Endocrinol Metab.,2016 Nov 1;311(5).

[0080] Patricia B Williams,Elizabeth Crandall and John D Sheppard,2010,Azelastine hydrochloride,a dual-acting anti-inflammatory ophthalmic solution,for treatment of allergic conjunctivitis.Clinical Ophthalmology 2010:4 993-1001.

[0081] Casale T.The interaction of azelastine with human lung histamine H1,beta,and muscarinic receptor-binding sites.J Allergy Clin Immunol.1989;83:771-776.

[0082] Hazama H,Nakajima T,Hisada T,Hamada E,Omata M,Kurachi Y.Effectsofazelastine on membrane currents in tracheal smooth muscle cells isolatedfromthe guinea-pig.Eur J Pharmacol.1994;259:143-150.

[0083] Szelenyi I,Achterrath-Tuckermann U,Schmidt J,Minker E,Paegelow I,Werner H.Azelastine:A multifaceted drug for asthma therapy.AgentsActionsSuppl.1991;34:295-311.

[0084] Galatowicz G,Ajayi Y,Stern ME,Calder VL.Ocular antiallergiccompoundsselectively inhibit human mast cell cytokines in vitro andconjunctival cellinfiltration in vivo.Clin Exp Allergy.2007;37:1648-1656.

[0085] Ciprandi G,Pronzato C,Passalacqua G,et al.Topical azelastinereduceseosinophil activation and intercellular adhesion molecule-1 expressionon nasalepithelial cells:An antiallergic activity.J Allergy ClinImmunol.1996;98(6 Pt1):1088-1096.

[0086] Simons FE,Simons KJ.Clinical pharmacology of new histamine H1receptorantagonist.Clin Pharmacokinet.1999;36:329-352.

[0087] Aiko Hatakeyama,2008,Azelastine hydrochloride on behavioralandpsychological symptoms and activities of daily living in dementiapatients.Geriatr Gerontol Int 2008;8:59-61.

[0088] Duraisamy Kempuraj, et al. 2003, Azelastine Inhibits Secretion of IL-6, TNF-alpha and IL-8 as Well as NF-kappaB Activation and IntracellularCalciumIon Levels in Normal Human Mast Cells. Int Arch Allergy Immunol. 132(3), 231-9 Nov 2003.

[0089] Kazunori Yoneda, et al. 1997, Suppression by Azelastine HydrochlorideofNF-KB Activation Involved in Generation of Cytokines and NitricOxide. Japanese Journal of Pharmacology, 73: 145-53.

[0090] Loyd Allen, Ansel's Pharmaceutical Dosage Forms and Drug Delivery Systems, Tenth (2013).

[0091] Sarfaraz K.Niazi,Handbook of Pharmaceutical ManufacturingFormulations Volumes 1-6.

[0092] The present invention has been described with reference to specific embodiments having various features. Based on the disclosure provided above, it will be apparent to those skilled in the art that various modifications and variations may be made in the practice of the present invention without departing from the scope or spirit of the present invention. Those skilled in the art will recognize that, based on the requirements and specifications of a given application or design, the disclosed features may be used alone, in any combination, or omitted. When an embodiment refers to "comprising" certain features, it will be understood that the embodiment may alternatively consist of or be substantially composed of any one or more of the features. Any method disclosed herein may be used with any composition disclosed herein or with any other composition. Similarly, any disclosed composition may be used with any method disclosed herein or with any other method. In view of the specification and practice of the present invention, other embodiments of the present invention will be apparent to those skilled in the art.

[0093] It should be noted that, in the case of providing a numerical range in this specification, each value between the upper and lower limits of the range is also specifically disclosed. The upper and lower limits of these smaller ranges may also be independently included in the range or excluded in the range. Unless the context clearly specifies otherwise, the singular forms "a", "an" and "the" include plural indicators. It is intended to consider that the description and embodiments are exemplary in nature and that the changes that do not deviate from the essence of the present invention fall within the scope of the present invention. In addition, all references cited in the present disclosure are independently introduced into this paper by reference in their entirety and are equally intended to provide an effective way to supplement the disclosure of the present invention and to provide background knowledge that details the level of ordinary skills in the art.

Claims

1. A pharmaceutical composition comprising: Azelastine or a pharmaceutically acceptable salt of azelastine; melatonin; and One or more pharmaceutically acceptable excipients.

2. The pharmaceutical composition according to claim 1, wherein the azelastine or the pharmaceutically acceptable salt of azelastine is present in the pharmaceutical composition in an amount ranging from about 1 mg to about 10 mg.

3. The pharmaceutical composition of claim 1, wherein the melatonin is present in the pharmaceutical composition in an amount ranging from about 2 mg to about 20 mg.

4. The pharmaceutical composition of claim 2, wherein the melatonin is present in the pharmaceutical composition in an amount ranging from about 2 mg to about 20 mg.

5. The pharmaceutical composition according to claim 1, wherein: The azelastine or a pharmaceutically acceptable salt of azelastine is present in the pharmaceutical composition in an amount ranging from about 1 mg to about 10 mg; and The melatonin is present in the pharmaceutical composition in an amount ranging from about 5 mg to about 20 mg.

6. The pharmaceutical composition according to claim 1, wherein the pharmaceutically acceptable salt of azelastine is azelastine hydrochloride.

7. The pharmaceutical composition according to claim 2, wherein the pharmaceutically acceptable salt of azelastine is azelastine hydrochloride.

8. The pharmaceutical composition of claim 1, wherein the pharmaceutically acceptable salt of azelastine is azelastine hydrochloride, and the azelastine hydrochloride is present in the pharmaceutical composition in an amount of up to about 10 mg.

9. The pharmaceutical composition of claim 6, wherein the azelastine hydrochloride is present in an amount ranging from about 1 mg to about 10 mg.

10. The pharmaceutical composition according to claim 1, wherein the pharmaceutical composition is formulated as an oral pharmaceutical dosage form.

11. The pharmaceutical composition according to claim 10, wherein the oral pharmaceutical dosage form is in solid form or liquid form.

12. A method comprising: administering the pharmaceutical composition to a patient suffering from insomnia or a symptom thereof; The pharmaceutical composition comprises azelastine or a pharmaceutically acceptable salt of azelastine and melatonin.

13. The method according to claim 12, wherein the pharmaceutical composition is administered to the patient in oral solid or liquid form once or twice a day or once every 2 days, 3 days or 4 days.

14. The method of claim 12, wherein the azelastine or a pharmaceutically acceptable salt of azelastine is present in the pharmaceutical composition in an amount ranging from about 1 mg to about 10 mg.

15. The method of claim 14, wherein the melatonin is present in the pharmaceutical composition in an amount ranging from about 2 mg to about 20 mg.

16. The method of claim 12, wherein the melatonin is present in the pharmaceutical composition in an amount ranging from about 2 mg to about 20 mg.

17. The method of claim 16, wherein the azelastine or a pharmaceutically acceptable salt of azelastine is present in the pharmaceutical composition in an amount ranging from about 4 mg to about 10 mg.

18. The method of claim 12, wherein the azelastine or a pharmaceutically acceptable salt of azelastine and the melatonin are present in the pharmaceutical composition in synergistically effective amounts.

19. The method of claim 12, wherein the pharmaceutical composition is administered to the patient for a period of up to 8 weeks.

20. The method of claim 12, wherein the pharmaceutical composition is administered to the patient for a period of at least 4 weeks.

21. Use of a pharmaceutical composition for the preparation of a medicament for treating a patient suffering from insomnia or one or more symptoms thereof, wherein the pharmaceutical composition comprises a composition according to any one of claims 1 to 11 and / or the use relates to any of the methods or method steps according to claims 12 to 20.

22. A pharmaceutical composition for use in treating insomnia or one or more symptoms thereof, wherein the medicament comprises the composition of any one of claims 1 to 11 and / or the use involves any of the methods or method steps of claims 12 to 20.